Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

232
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
232
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.7K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.7K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

196
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
196
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

381
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
381
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

179
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
179
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

247
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
247

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erythrokeratodermia Variabilis et Progressiva 4 With KDSR Mutations: A Case Report.

The Journal of dermatology·2026
Same author

Research progress on composite nerve guidance conduits with immune-regulatory functions.

Frontiers in immunology·2025
Same author

Metabolic acclimation to warming links unexpected immune activation and sexual dimorphism attenuation in Xenopus tropicalis.

Communications biology·2025
Same author

Preparation of chitosan-modified Moringa A liposomes and its protective effect on acute alcoholic liver injury.

Journal of liposome research·2025
Same author

Podocyte RIPK3 Deletion Improves Diabetic Kidney Disease by Attenuating NF-κB p65 Driven Inflammation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Trends, inequalities, and cross-location similarities in global dementia burden and attributable risk factors across 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021.

International journal of surgery (London, England)·2025

Related Experiment Video

Updated: Jan 11, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.4K

Clinical Features and Long-Term Outcomes in 109 Pediatric Generalized Pustular Psoriasis.

Jiaying Li1,2, Zhaoyang Wang1,2, Chaoyang Miao1,2

  • 1Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.

Dermatology (Basel, Switzerland)
|November 18, 2025
PubMed
Summary

Pediatric-onset generalized pustular psoriasis (PGPP) flares decrease with age but remain common. Earlier onset PGPP is linked to more frequent flares, with biologics now the primary treatment.

Keywords:
Generalized pustular psoriasisPediatric dermatologySkin inflammation

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

744
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K

Related Experiment Videos

Last Updated: Jan 11, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.4K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

744
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K

Area of Science:

  • Dermatology
  • Pediatric Immunology
  • Clinical Research

Background:

  • Pediatric-onset generalized pustular psoriasis (PGPP) is a rare, challenging inflammatory condition.
  • Characterized by recurrent flares and complex management needs.

Purpose of the Study:

  • To review clinical features of PGPP.
  • To analyze flare patterns and identify triggers.
  • To evaluate current and evolving treatment options.

Main Methods:

  • Retrospective analysis of 109 PGPP patients (2006-2023).
  • Data collection via medical records and telephone surveys.
  • Analysis of flare frequency, duration, triggers, and treatment modalities.

Main Results:

  • Median onset age was 6 years; higher prevalence in males.
  • Respiratory infection was the most common trigger.
  • Flare frequency and duration decreased with age; earlier onset correlated with higher frequency.
  • Conventional therapies (acitretin) were common before 2020; biologics (secukinumab) are now prevalent.

Conclusions:

  • PGPP flares tend to decrease with age, but recurrence is frequent.
  • Early onset PGPP may be associated with increased flare frequency.
  • Biologic agents represent the current standard of care for PGPP.